Anika Therapeutics
Quarterly Financials
| Values in thousands | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
Revenue | $27,817 | $28,219 | $26,168 | $-1,290 |
Gross Profit | 15,584 | 14,363 | 14,681 | 22,565 |
EBITDA | -833 | -2,764 | -2,692 | 26,529 |
EBIT | -2,236 | -4,180 | -4,284 | 24,717 |
Net Income | -2,329 | -3,970 | -4,873 | -21,865 |
Net Change In Cash | 27,817 | 28,219 | 26,168 | -1,290 |
Free Cash Flow | 4,983 | -1,656 | -2,954 | 275 |
Cash | 57,990 | 53,167 | 53,371 | 55,629 |
Basic Shares | 14,361 | 14,331 | 14,297 | 14,721 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $119,907 | $120,792 | $156,236 | $147,794 |
Gross Profit | 75,998 | 82,532 | 93,576 | 82,943 |
EBITDA | 3,020 | 15,061 | -4,913 | -4,163 |
EBIT | -5,101 | 844 | -19,400 | -18,480 |
Net Income | -56,385 | -82,667 | -14,859 | 4,134 |
Net Change In Cash | 119,907 | 120,792 | 156,236 | 147,794 |
Cost of Revenue | -7,929 | -1,500 | ||
Free Cash Flow | -2,331 | -7,215 | -3,077 | 3,254 |
Cash | 55,629 | 68,740 | 86,327 | 94,386 |
Basic Shares | 14,721 | 14,656 | 14,561 | 14,634 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-12-31 | $0 |
2025-09-30 | $0.04 |
2025-06-30 | -$0.33 |
2025-03-31 | -$0.06 |
